Skip to main content
Earle Burgess, MD, Oncology, Charlotte, NC

Earle F Burgess MD

Oncology•Charlotte, NC

Genitourinary Oncology, Hematologic Oncology

Genitourinary Oncology Section Chief; Medical Director, Clinical Trials Levine Cancer Institute; Associate Professor of Medicine, Atrium Health

Join to view full profile

  • 10660 Park RdSte 2100Charlotte, NC 28210

  • Phone+1 980-442-0410

  • Fax+1 980-442-9341

Dr. Burgess is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Burgess' full profileAlready have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2009
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2004
  • Medical College of Georgia at Augusta University
    Medical College of Georgia at Augusta UniversityClass of 2002
  • Wake Forest University
    Wake Forest UniversityB.S., Magna Cum Laude, 1997

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2027
  • SC State Medical License
    SC State Medical License 2009 - 2015
  • TN State Medical License
    TN State Medical License 2004 - 2009
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2014, 2017
  • CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2013-2014, 2017
  • CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2013-2014, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Individualized Management of Advanced Bladder Cancer: Where Do We Stand?  
    Burgess EF, Urologic Oncology, 1/1/2015
  • Prostate Cancer: What Did We Learn from the 2012 Annual Tumors-What Have We Learned in 35 Years?  
    Riggs S, Burgess EF, Gaston D, Raghavan D, Oncologist, 1/1/2014
  • Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein Complexes  
    Burgess EF, Ham AL, Tabb DL et al, Proteomics-Clinical Applications, 1/1/2008

Books/Book Chapters

  • Cancer Medicine 
    Chapter: Urothelial Cancer 
    Raghavan D, Cote R, Burgess EF, Riggs S and Haake MJohn Wiley and Sons, Inc., Hoboken, NJEdition 9th,2017
  • Cancer Medicine 
    Chapter: Renal Cell Carcinoma 
    Burgess EF, Riggs SB, Rini BI and Raghavan DJohn Wiley and Sons, Inc., Hoboken, NJEdition 9th,2017
  • Textbook of Uncommon Cancer 
    Chapter: Penile Carcinoma 
    Mark JR, Riggs SB, Graham DL, McHaffie DR, Livasy CA and Burgess EFJohn Wiley and Sons, Ltd., Chichester, UKEdition 5th,2017

Abstracts/Posters

  • Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.
    Dawson N, Geynisman D, Burgess E, Somer B, Arguello D, Hauke R, Vaena D, Raghavan D, Heath E, J Clin Oncol, 1/1/2018
  • Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterati...
    Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, OHagan A, Avadhani A, Zhong B, Stuyc..., Clin Oncol, 1/1/2018
  • Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis o...
    Siefker-Radtke A, Necchi A, Rosenbaum E, Culine S, Burgess E, O'Donnell P, Tagawa S, Zakharia Y, OHagan A, Avadhani A, Zhong B, Santiago-Walker A, Roccia T, Loriot Y, J Clin Oncol, 1/1/2018

Lectures

  • A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73▿
    A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73▿August 4th, 2020
  • A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with mCSPC
    A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with mCSPCJune 4th, 2018
  • ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess
    ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle BurgessNovember 15th, 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Earle Burgess, Dr. Earle Burgess, MD, Dr. E Burgess, Dr. Earle F Burgess